TIA-1

Product Description

TIA-1 antibody (T-cell intracytoplasmic antigen) is expressed in lymphocytes processing cytolytic potential. Studies show that 60 to 70% of anaplastic large cell lymphoma reacts with TIA-1. Studies also indicate that TIA-1 reacts with most large granular lymphocytic leukemias, hepatosplenic T-cell lymphomas, intestinal T-cell lymphomas, NK-like T-cell lymphomas, NK cell lymphomas, nasal T/NK-cell lymphomas, subcutaneous T-cell lymphomas and pulmonary angiocentric lymphomas of T-or NK-phenotype. All B-cell lymphomas, Hodgkin’s and lymphoblastic leukemias were negative for TIA-1.

Specifications

Regulatory Notice: Biocare’s IVD-labeled products comply with US-FDA and European IVDD regulation. Other regions may have additional requirements for such labeling, please contact your local distributor.

1. Dukers DF et al. A cytotoxic phenotype does not predict clinical outcome in anaplastic large cell lymphomas. J Clin Pathol 1999 Feb;52(2):129-36.
2. Kanavaros P et al. Cytotoxic protein expression in non-Hodgkin’s lymphomas and Hodgkin’s disease. Anticancer Res 1999 Mar-Apr;19(2A):1209-16.
3. Center for Disease Control Manual. Guide: Safety Management, NO. CDC-22, Atlanta, GA. April 30, 1976 “Decontamination of Laboratory Sink Drains to Remove Azide Salts.”
4. National Committee for Clinical Laboratory Standards (NCCLS). Protection of laboratory workers from infectious diseases transmitted by blood and tissue; proposed guideline. Villanova, PA 1991;7(9). Order code M29-P.